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Re-expression of CD14 in Response
to a Combined IL-10/TLR Stimulus
Defines Monocyte-Derived Cells With
an Immunoregulatory Phenotype
Sören Krakow, Marie L. Crescimone, Charlotte Bartels, Verena Wiegering, Matthias Eyrich,
Paul G. Schlegel and Matthias Wölfl*
Department of Hematology, Oncology and Stem Cell Transplantation, University Children’s Hospital, University of Würzburg,
Würzburg, Germany
Interleukin 10 is a central regulator of the antigen-presenting function of myeloid cells.
It exerts immunomodulatory effects in vivo and induces a regulatory phenotype in
monocyte-derived cells in vitro. We analyzed phenotype and function of monocytic
cells in vitro in relation to the cytokine milieu and the timing of TLR-based activation.
In GM-CSF/IL-4 cultured human monocytic cells, we identified two, mutually exclusive
cell populations arising from undifferentiated cells: CD83+ fully activated dendritic cells
and CD14+ macrophage like cells. Re-expression of CD14 occurs primarily after a
sequential trigger with a TLR signal following IL-10 preincubation. This cell population
with re-expressed CD14 greatly differs in phenotype and function from the CD83+ cells.
Detailed analysis of individual subpopulations reveals that exogenous IL-10 is critical for
inducing the shift toward the CD14+ population, but does not affect individual changes
in marker expression or cell function in most cases. Thus, plasticity of CD14 expression,
defining a subset of immunoregulatory cells, is highly relevant for the composition of
cellular products (such as DC vaccines) as it affects the function of the total product.
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INTRODUCTION
Cells of myeloid origin acquire immunostimulatory and immunoregulatory functions depending
on the respective milieu. Differentiated type 1 cells, such as type 1 macrophages and dendritic
cells, are essential to mount an inflammatory, and antigen-specific response (1). Alternatively
activated macrophages, myeloid-derived suppressor cells (MDSCs), and regulatory dendritic cells
(DCs) exert multiple immunoinhibitory functions (2–4). In human disease, these cells effectively
link innate, and adaptive immunity: e.g., immunosuppressive tumor-associated macrophages can
be found in various tumor-entities (5), and MDSCs circulate the blood of cancer patients (4). In
contrast, alloreactivity in acute GvHD may be partially based on the dysbalance of the myeloid cell
compartment after stem cell transplantation (6, 7).
Monocyte-derived cells, generated in vitro, share many of the characteristics of naturally
occurring myeloid cell types. Once activated, monocyte-derived dendritic cells are capable of
mounting a primary T-cell response, making them central to many tumor vaccination efforts.
Alternative culture protocols lead to a regulatory functional profile, providing a cellular tool to
address auto- and alloreactivity. As monocytes are readily available, these approaches are being
evaluated in clinical trials (8).
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Interleukin-10 (IL-10) is a master regulator for generating
immunomodulatory cells. Depending on the culture conditions
and the timing of IL-10 contact, monocyte-derived cells acquire
different phenotypical and functional properties. Nomenclature
is ambiguous, making it difficult to draw a general picture.
Monocyte-derived macrophages are usually generated by culture
with M-CSF and IL-10, whereas GM-CSF and IL-4 is thought
to promote a type 1 macrophage/dendritic cell phenotype (9).
Within protocols using GM-CSF/IL-4-cultured monocytic cells,
the timing of the first contact with IL-10 appears to be crucial:
when added directly to CD14+ monocytes, differentiation
toward a full dendritic phenotype is thwarted. The cells are
described as expressing less costimulatory molecules and less
HLA-DR and maintain CD14 (10). Functionally, reduced T-
cell stimulatory capacity is documented. Such monocyte-derived
cells differentiated with GM-CSF, IL-13, and IL-10, have been
simply classified as “macrophages” by Allavena et al. (11).
Recently, using a similar approach with GM-CSF, IL-4, and IL-
10 (from the start of culture) Heine et al. describe the resulting
cells as CD14+HLA-DRlow “MDSC-like” cells (12). MDSC
have been initially described in the murine system, whereas
MDSC in humans still lack definitive classification (4). However,
some subsets such as such as LIN−HLA-DR−/low, CD14+HLA-
DR−/low, and CD15+HLA-DR−/low have been defined (13).
CD14+HLA-DRlow MDSC have been identified in patients with
various cancer types and are associated with a less favorable
prognosis (4, 14).
In somewhat parallel investigations, it was noted, that
immature dendritic cells, developing under the influence of
GM-CSF/IL-4, may be directed toward a regulatory phenotypic
and functional profile, once they are in contact with IL-10
(15). As before, it was noted that costimulatory molecules
are downregulated, while expression of inhibitory molecules
such as ILT4 (16), and PD-L1 increases (17). Again, a robust
immunoinhibitory capacity has been noted, as T-cell tolerance is
induced. Cells generated with this type of protocol were termed
“regulatory dendritic cells,” as a fraction, but by far not all, of the
cells will express the DC-marker CD83.
In this study, we distinguish between different cell populations
arising from standard culture conditions of human GM-CSF/IL-
4 cultured monocytic cells in response to IL-10 and an
activating trigger. The monocytic cells were primed with IL-
10 shortly before triggering them via a TLR. Surprisingly two
mutually exclusive populations with distinct phenotypic profiles
can be distinguished: CD14+ cells matching in many aspects
the phenotypical and functional aspects of MDSC/DCreg and
CD83+ cells, displaying markers of type 1 DC. This CD14+
cell population arises from non-differentiated cells, that had
already downregulated CD14 as a consequence of GM-CSF/IL-
4 culture and then re-express CD14. A fraction of these
CD14+CD83− cells can routinely be detected following certain
TLR-triggers (such as R848 or LPS) even without exogenously
added IL-10, but a binary signal from IL-10 and a TLR-
trigger is required for maximal differentiation toward this
cell type.
Using CD14 as the defining positive marker, we show that
rather than a direct effect of IL-10 on individual markers or a
specific function, IL-10 shifts a whole cell population toward this
altered CD14+ phenotype, while, contrary to the paradigm,many
individual markers within this population remain unaffected
from the exogenous IL-10.
MATERIALS AND METHODS
Terminology
Classification and terminology of dendritic cell and macrophage
subsets remain a matter of intense discussions. Historically,
monocyte-derived DCs were described either as “immature,”
when treated with GM-CSF and IL-4 only, or “mature” when
an activating stimulus had been provided (17). Monocyte-
derived cells treated with modifying molecules such as IL-
10, rapamycin or corticosteroids have been termed “regulatory
DCs.” A unified nomenclature based on ontogeny has been
proposed, which only refers to these cells as “monocyte-derived”
(18). For the clearest terms possible, we will refer to the cells
evaluated in this work as follows: all cell populations used in
this work are human, monocyte-derived cells (moC). Generally,
the starting population are cells cultured in GM-CSF/IL-4
containing medium (formerly ‘immature DC’), which we refer
to as “GM/IL4moC.” Any further treatment (e.g., with IL-10
or R848) replaces the GM/IL-4 indicator (e.g., IL10/R848moC)
implying that this treatment was added on top of the GM/IL-4
culture. If various activating conditions are summarized, “act”
is put instead of the specific stimulus (e.g., IL10/actmoC). Once
cells are stimulated, we refer to them as “activated” rather
than “mature.” Morphological distinctions based on CD14 and
CD83 expression are added, when these subgroups are evaluated
separately (e.g., IL10/R848moC
CD14+). Functional differences such
as a more regulatory or inflammatory profile, are discussed as
functions in the paper but are not part of the terminology.
Cell Culture
Peripheral blood mononuclear cells were obtained and
cryopreserved from healthy donors, who had been eligible
to donate blood in the local blood bank, by washing out
leucocyte depletion filter chambers that collect leucocytes as a
by-product to platelet collection. Experiments performed with
such leucocytes, following pseudonymization of the donor, do
not require informed consent according to a decision of our IRB.
For the generation of moC, standard procedure was to allow cells
to adhere to 6-well plastic dishes for 2 h and subsequently remove
the non-adherent fraction by washing. Cells were then cultured
in DC Medium (Cellgenix, Freiburg, Germany), supplemented
with 1% human serum (Biochrom, Berlin, Germany) and 800
U/ml GM-CSF (Gentaur, Aachen, Germany) and 100 U/ml
IL-4 (Peprotech, Hamburg, Germany). Forty eight hours after
initiation of the culture, fresh mediumwas added, including GM-
CSF and IL-4. For IL10/R848moC, IL-10 (40 ng/ml; Peprotech,
Hamburg, Germany) was added at least 1 h before adding
the activation stimulus. As activation stimuli, the following
reagents were used: R848 (2µg/ml; Invivogen, San Diego, CA,
USA); LPS(E. coli) (30 ng/ml; Sigma, St. Louis, Missouri, USA);
MPLA-SM (1µg/ml, Invivogen, France); Poly(I:C) (HMW,
10µg/ml, Invivogen, France). Additional cytokines used in the
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assays were: TNFα (10 ng/ml; Peprotech, Hamburg, Germany),
IL-1ß (10 ng/ml, Cellgenix, Freiburg, Germany). Cells were
evaluated 16–48 h after activation, depending on the individual
question of the assay. Functional grade anti-IL10-antibody and
anti-IL10R-antibody was purchased from eBioscience.
Flow Cytometry
Analysis of cell cultures was performed on a FACS Canto II
flow cytometer (BD) using 3 lasers. Staining protocols followed
standardized procedures at optimized antibody concentrations.
The antibodies against the following antigens were used:
CD14 (PE; MφP9; BD Biosciences), CD36 (PerCpCy5.5;
eBioNL07; eBioscience), CD80 (PerCpCy5.5; 2D10; Biolegend)
CD83 (Brilliant Violet 421TM; HB15e; Biolegend) CD85d
(APC; 42D1; eBioscience), CD85k (APC; ZM4.1; eBioscience)
CD86 (PerCPCy5.5; IT2.2; Biolegend), CD91 (APC; A2MR-
a2; eBioscience), CD163 (FITC; GHI/61; Biolegend), CD206
(FITC; 15-2; Biolegend), CD273 (APC; MIH18; Biolegend)
CD274 (FITC; MIH1; BD Biosciences), CD279 (FITC; MIH4;
eBioscience), CX3CR1 (PerCpCy5.5; 2A9-1; Biolegend) Viability
Dye (eFluor 780; eBioscience).
Endocytosis Assay
Experimental groups were seeded in 96 well-plates using DC
medium without serum or cytokines. APC-Dextran (MW:
10,000; 200µg/ml; Invitrogen) was added at t0. At defined
time points (0, 20, 40, 60, 90min), cells were harvested and
immediately washed using cold PBS and placed on ice until
FACS analysis.
ELISA
For IL-6 ELISA, supernatant from the differentially activated
groups (3 × 106 cells/group) was frozen and later analyzed.
ELISAs were performed using kits from ThermoFisher, following
the manufacturer’s protocol.
T-Cell-Assays
Priming of naïve T-cells was performed following the
protocol published previously in detail (19, 20). Briefly,
CD45RO−CD57−CD8+ T-cells were stimulated at a 10:1 ratio
with moC, pulsed with the HLA-A2-restricted, heteroclitic
peptide Melan-A(26−35(A27L), immunograde (ELAGIGILTV;
jpt, Berlin, Germany). Cells were grown in Cellgenix GMP DC
Medium (Cellgenix, Freiburg, Germany). IL-21 (Peprotech,
Hamburg, Germany) was added at the start of culture. IL-7
and IL-15 (both Peprotech, Hamburg, Germany) was added
on day 3 of culture and refreshed every 2–3 days. Cells were
analyzed on day 10 of culture, taking cell counts and performing
MHC-multimer-staining (Immudex, Copenhagen, Denmark).
Statistics
Statistical analysis was performed using GraphPad Prism. Error
bars always indicate standard deviation. T-test or two-way
ANOVA was chosen as appropriate and analysis was done taking
paired observations into account and correcting for multiple
comparisons (Tukey).
RESULTS
CD14 Is Re-expressed on moC Following
an IL10/R848 Trigger
For all experiments shown here, human monocyte-derived
dendritic cells were generated by selecting the plastic adherent
fraction of the cells as described in the methods. The resulting
adherent cell population predominantly expresses CD14, which
is gradually lost throughout the culture in GM-CSF and IL-
4 containing medium. Sometimes retained CD14 expression is
reported (8, 10) and is attributed to incomplete differentiation
due to culture conditions. Therefore, we initially thought of
CD14 as a marker that is gradually lost when monocytes
differentiate toward dendritic cells and we expected to see a
differentiation stop once IL10 is added to the culture. Indeed,
when IL-10 alone was added on day 3 for 24 h, we noticed
a higher fraction of CD14+ cells, as was already outlined in
earlier work (15). However, we also noticed a fraction of the
moC expressing even higher levels of CD14, once they had
been stimulated with the TLR7/8 agonist R848 and this fraction
significantly increased when the cells were pre-incubated with IL-
10 followed by R848, an example of which is shown in Figure 1A.
CD14 expression wasmutually exclusive to CD83 expression, as a
marker for fully activated DC. To assess whether these differences
were truly dependent of the culture conditions, or whether
factors inherent to different donors contributed to the results, we
repeated this experiment with cell preparations from 19 different
donors. Experiments were performed by 3 different researchers.
As shown in Figure 1B, the range of CD14 expression for each
individual donor is high in each of the experimental groups.
Specifically GM/IL4moC, without any additional manipulation,
showed a mean CD14 expression of 4.6% with a standard
deviation of 5.5. One explanation may be, as discussed later, that
donor-inherent factors (e.g., current in vivo cytokine milieu at
the time of donation) may influence cell differentiation in vitro.
Despite this rather large inter-donor variation, the effect of IL-10
on upregulation of CD14, especially when combined with R848
activation, was highly statistically significant (p < 0.0001, Two-
way ANOVA; Figure 1B, right panel). Re-expression of CD14
was dose-dependent, with most robust effects starting in the
range of 4–40 ng/ml of IL-10 (Figure 1C). These CD14+ cells
emerge from the CD14− population, as during culture in GM-
CSF/IL-4 CD14-expression is rapidly lost (Figure 1D, left). Even
if residual CD14+ cells are depleted, using CD14-microbeads
prior to IL-10 exposure (day 3), re-expression of CD14 occurs
within 24 h after incubation with IL-10 and R848 (Figure 1D,
right). Nevertheless, one might argue that 4-day cultured cells
are still too undifferentiated and the observed results may be
partially affected by incomplete downregulation. We, therefore,
prolonged cell culture with GM-CSF and IL-4 for 7 days, and
then reevaluated CD14 expression in relation to IL-10 and/or
R848. Seven-day-cultured GM/IL4moC expressed even less CD14
and adding either IL-10 or R848 alone only resulted in a slight
increase in CD14+ cells. Combining IL-10 and R848, we observed
a similar increase in CD14+ cells after a 7-day culture period
(Figure 1E) to what we had observed in multiple donors in
4-day cultured cells (Figure 1B). Likewise, CD83 upregulation
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occurred independently of the culture time (4 vs. 7d) but was
hindered by IL-10, as has been described in many papers. Of
note, excess amounts of GM-CSF or IL-4 (10-fold) had no effect;
specifically, it did not counteract the observed upregulation of
CD14 (three experiments, data not shown).
As we observed a small percentage of CD14+ cells following
activation with R848 only, we suspected that this fraction
responded to endogenous IL-10 produced upon TLR-triggering.
Experimentally this was confirmed by blocking IL-10 signaling
using anti-IL-10- and anti-IL-10R-antibodies. Original plots of
one representative experiment, as well as the summary of all 7
experiments are shown in Figure 1F. Even with the rather big
variation of the CD14+ fraction following R848 activation, the
results suggest a significant effect of IL-10 blockade in conditions
were no exogenous IL10 was added (left panels). As controls, we
also show the experiments with exogenous IL10 added, and then
blocked, which was highly statistically significant. We conclude
that endogenous IL10, produced during stimulation with R848,
contributes to upregulation of CD14 in a fraction of these cells.
CD14 Re-expression Depends on the
Activating Signal and the Pre-existing
Cytokine Milieu
We next asked whether re-expression of CD14 depends
on the stimulus used to activate the cells. Besides R848,
triggering through TLR7/8, we also tested LPS(E. coli), triggering
predominantly via TLR4, monophosphoryl lipid A (MPLA), a
less toxic derivative of LPS, used as an adjuvant in vaccines,
Poly(I:C), a TLR3 stimulus as well as a maturation cocktail
based on IL-1ß, TNFα, and PgE2. The intrinsic capacity of these
stimuli, to induce CD14 expression without exogenous IL-10,
varied considerably, with LPS inducing a significant fraction of
CD14+ cells, whereas cytokine activated cells showing the most
significant CD83+ fraction and only a fewCD14+ cells. Poly (I:C)
alone also did not increase CD14+ cell numbers, but expression
of CD83 was poor as well. However, once non-committed cells
had been pre-incubated with IL-10, a robust increase in CD14+
cells was observed regardless of the activation stimulus used.
Quantitatively R848 and LPS still had the most significant impact
on the CD14+ fraction, but re-expression was also observed
with Poly (I:C) or cytokines (Figures 2A,B). Next, we wanted
to know, whether non-committed cells could be sensitized for
full activation when placing them in a more pro-inflammatory
environment early on. GM/IL4moC were exposed to titrated
amounts of TNFα after 48 h of culture. One group was followed
by IL10 incubation 24 h later, whereas the other received no
exogenous IL10. Subsequently all cells were stimulated with R848
1 h later. Twenty four hours later, cells were analyzed by FACS. As
seen in original plots of one examplary experiment [Figure 2C
(upper panel)], TNFα greatly reduced CD14 expression in cells
activated with R848 only. When exogenous IL-10 was added,
preincubation with as little as 0.1 ng/ml TNFα still reduced
CD14 expression significantly, whereas the increase in CD83-
expression could not be fully restored (Figure 2C, bottom panel).
When combining data from 5 experiments with different donors,
0.1 ng/ml TNFα was sufficient to significantly inhibit CD14
upregulation (Figure 2D).
IL-10 Boosts the CD14+ Subgroup With a
Distinct Phenotypic Profile
In all experiments so far, CD14 expression and CD83 expression
was mutually exclusive, suggesting that CD14 is a reliable marker
for an alternative activation pathway of GM/IL4moC. By gating on
these two populations, we were able to compare fully activated
moCCD83+ to the alternatively activated moCCD14+. A third
group, which is CD83−/CD14− was not taken into account
for this analysis. What became evident immediately, is that
moCCD14+ exhibit many of the phenotypical features formerly
attributed to “maturation-resistant DCs,” “tolerogenic DCs” or
CD14+MDSCs. Just like these cell populations, moCCD14+
displayed lower levels of costimulatory molecules such as CD80
and CD86. But the important finding here is, that within each
subgroup of cells, IL-10 had little direct effect on CD80, or CD86
expression (Figure 3). This seemingly contradicts previously
published data, as downregulation of costimulatory molecules is
often attributed to IL-10 (2, 17, 21, 22). Figure 3A depicts an
example of how phenotypes might be analyzed when looking at
total cells vs. CD14+ and CD83+ subgroups. To better evaluate
IL10 dose dependency on specific markers, Figure 3B shows
titration curves (mean of 3 different experiment and donors),
depicting patterns where IL-10 affects expression of a particular
marker in all groups (e.g., CD80), predominantly in one group
(e.g., CD163, CD273) or where the effects are only seen on
the total (mixed) population (e.g., CD86, ILT4), suggesting a
quantitative shift in the population rather than a direct effect
on expression.
This was statistically analyzed for different treatment groups
(at a fixed IL10 dose) (Figure 3C). As has been noted by
many groups, the difference between CD86 expression in
IL10-treated, activated cells vs. activated cells without IL10
treatment was highly statistically significant when analyzing total
cells. However, no difference in the expression level can be
observed when looking at CD14 and CD83 subgroups separately.
Thus, this difference is explained by the generally lower CD86
expression in moCCD14+ and the percentage-wise increase of
this cell fraction upon IL-10 preincubation. A very similar
pattern was observed for HLA-DR as a marker for MHC class
II expression (Figure 4). CD273 (PD-L2) was expressed at a
higher level in moCCD83+ (Figure 3), whereas no difference
was observed for CD274 (PD-L1) (not shown). ILT4 was
expressed at a much higher level on moCCD14+. In that case,
analysis of total cells would suggest a direct role of IL10 to
induce higher levels of ILT4, as has been described previously
(16). However, again, the difference is mainly explained by
the striking difference between moCCD14+ILT4+ cells vs. the
moCCD83+ILT4low cells. Broadening the spectrum of phenotypic
markers, we also included markers described to characterize
macrophage differentiation. The scavenger receptor CD163
was exclusively expressed on moCCD14+. Exogenous IL-10
enhanced its expression, confirming an IL10-dependent dose-
dependency for this receptor (23). CD206(mannose-receptor)
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FIGURE 1 | IL-10 in combination with R848 induces re-expression of CD14 in GM-CSF/IL4-cultured monocytic cells (A). Individual plots of cells on d5 of culture after
24 h-incubation R848 (2µg/ml) without and with IL-10 (40 ng/ml) pre-incubation (1 h), or the combination (B). Summary of 19 different experiments from different
healthy donors. (Two-way ANOVA for multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001) (C). IL-10 dose dependent increase of the
percentage of CD14+ cells in combination with a fixed dose of R848 (2µg/ml) (D). Left: Downregulation of CD14 on monocytes during culture in GM-CSF/IL-4
(before experimental treatment): %CD14+: black solid: d1 (94%); dotted: d2 (71%); dashed: d3 (12%); thin solid, tinted: d5 (without activation) (8.6%) (one of 3
experiments). Right: Upregulation of CD14 on day 5 of culture in cells, after treatment on day 4: dotted: IL-10/R848 (33%); solid blue: IL-10/R848 treated, after CD14
depletion on d4 (27%); dashed: R848 only (15%), light blue,tinted: R848(only) after CD14-depletion on d4 (10%) (E). Comparison of %CD14+ cells (left) and %CD83+
cells (right) after the respective treatment following a 4 day (black) culture or a 7 day (gray) culture in GM/IL-4 (n = 3) (F). Effect of IL-10 blockade on CD14
re-expression. Functional grade anti-IL10-antibody and anti-IL10R-antibody were added prior to preincubation with IL-10 or prior to R848 addition. CD14 and CD83
expression were measured 16 h later. Examplary plots and a summary from 7 different donors are shown.
remains expressed in IL10/R848moC
CD14+ as is expression of
CD282 (TLR2) (Figure 4). CX3CR1, another macrophage-
related marker, also was detected exclusively on moCCD14+ but
was not influenced by IL-10 directly (not shown).
In summary, the phenotypic analysis showed that IL-
10 pre-incubation before R848 stimulation gives rise to a
macrophage-like, CD14+ cell population with increased
CD163, CD206, CD282, CX3CR1, and ILT4 expression, and
a different level of costimulatory molecules. Contrasting
previous interpretations, significant direct effects on marker
expression caused by exogenous IL-10, were only seen
for CD163, whereas the majority of the effects stems
from the shift toward the CD14+ population supported
by IL-10.
Frontiers in Immunology | www.frontiersin.org 5 June 2019 | Volume 10 | Article 1484
Krakow et al. Heterogeneity in Monocyte-Derived Cells
FIGURE 2 | CD14 upregulation depends on IL-10 and the maturation stimulus (A). Monocytes, cultured in GM-CSF/IL-4, were either preincubated with IL-10 or not,
and subsequently stimulated for 16–18 h with the indicated substances. Cells were evaluated for CD14 and CD83 expression the following day (B). Summary from n
= 3 experiments (C). TNFα-preincubation for 24 h prior to adding IL10 hinders CD14 upregulation. Upper row: no IL10 addition, lower row with IL-10 (D). Summary of
5 independent experiments, showing the absolute % of CD14 depending on TNFα-preincubation without or with exogenous IL-10 (left, Two-way-ANOVA for multiple
comparisons, *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). The right panel shows the relative inhibition of CD14 expression by TNFα, taking the %CD14
without TNFα of each individual experiment as the reference point (100%). % Inhibition is calculated as: [1-(%CD14(sample)/%CD14(ref.point)] × 100. As these are
calculated values from the original data shown in the left panel, no statistical test is shown in this panel.
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FIGURE 3 | Phenotypic changes of moC depending on IL-10 pre-treatment. moC were pre-treated with IL-10 (40 ng/ml) or not. Cells were then activated using R848
and stained 16 h later. (A) Representative histograms for individual markers. Solid lines represent cell populations from the control group without IL-10. Dotted
line/tinted filling represent cell populations from the IL-10 treated group. The first panel represents analysis of total cells according to the live scatter gate. The middle
panel shows histograms from cells within the CD14+ gate. The right panels show histograms from the CD83+ population. Numbers in each plot indicate the Median
fluorescence intensity; —indicates the control group without IL-10, + indicates the IL-10 group. (B) Median fluorescence of individual markers (indicated on the left of
the figure), in relation to the IL-10 concentration. Black circles indicate analysis of total cells, red triangles indicate CD83+ cells and blue squares indicate CD14+ cells.
The left panels show mean absolute values from 3 independent experiments. The right panels show the change from the respective baseline (0 ng/ml) in percent. (C)
Mean with SD from 5 independent experiments using 40 ng/ml IL-10. Black columns (left) represent total cells, blue columns (middle) represent the CD14+
population, red columns (right) represent CD83+ cells. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
Other Non-IL-10 Based Approaches for
Regulatory DC Induce a Different
Phenotype in moC
These phenotypic changes in response to exogenous IL-10,
have been typically described for regulatory DC, but cells
are often evaluated as one population, not taking differential
CD14 expression into account. Using IL-10 to generate such
“regulatory DC” is a crucial concept for the use of such
immunomodulatory cells clinically (24). In light of the re-
expression of CD14 in cultures treated with IL-10, we wanted to
assess alternative protocols to generate regulatory DC. We tested
two different protocols: pre-incubation either with rapamycin
(25) or corticosteroids (dexamethasone) (26–28), each time
followed by R848-activation (Figure 4). Rapamycin preceding
R848 did not induce any CD14 re-expression, whereas as small
CD14+ population was observed following dexamethasone pre-
incubation and subsequent activation with R848. Of note, when
adding IL-10 on top of either dexamethasone or rapamycin,
diverging populations were observed: dexamethasone had
additive and similar effects on the phenotype of the CD14+
cells, thus enhancing expression of CD14 itself, but also CD163,
CD282, CD206, and ILT4. In contrast rapamycin suppressed
CD14 re-expression to some extent and blocked IL-10 mediated
CD163 expression. Thus, phenotypical differences in the type of
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FIGURE 4 | Phenotypic changes in response to other protocols used for generating regulatory DCs. moC were incubated either with IL10 (40 ng/ml), rapamycin
(100 ng/ml) or dexamethasone (100 nM) (for 16 h) or left alone. All groups were then activated with R848 (and a second addition of the modulating substance) and
stained 24 h later. The light pink population represents CD83+ cells, the dark blue population represents CD14+ cells. CD14−CD83− non-committed cells were
excluded in this analysis. Examplary plots of three experiments are shown.
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regulatory cells obtained by the various protocols, are divers, with
IL-10 dominating the differentiation toward macrophages.
IL-10 Affects Function by Shaping
Regulatory Subgroups Rather Than
Affecting Fully Differentiated
Cells Individually
Functionally IL10/actmoC resemble so-called “regulatory
dendritic cells.” Production of inflammatory cytokines ceases,
and cells have been shown to inhibit an allogeneic mixed
leucocyte reaction and induce T-cell tolerance (15). As
these regulatory characteristics have already been described
extensively, we wanted to explore functional characteristics with
a focus on CD14 expression.
We first re-evaluated production of IL-12 as the critical
inflammatory cytokine to drive TH1-responses. It is known, that
after IL-10 pre-incubation, IL-12 production is hindered. IL-
10 indeed reduces IL-12 production once cells are stimulated,
but this inhibition depends on the stimulus used (Figure 5A).
Technically, it was not possible, to analyze IL10/R848moC
CD14+
and IL10/R848moC
CD83+ separately, because CD14 upregulation
is blocked by the addition of brefeldin A, which is required
for the intracellular cytokine staining. However, one likely
interpretation is that the shift toward CD14+ cells, which do not
majorly contribute to IL-12 production (29), explains reduced
pro-inflammatory activity. Similarly, total IL-6 production was
reduced in the IL-10-pretreated group as assessed by ELISA
(Figure 5B). It is well-described that IL-10 treated GM/IL4moC
start to produce IL-10 endogenously; thus these particular
experiments were not repeated.
We next asked how endocytosis, a hallmark of macrophage
function, is affected within the different subgroups. Early work
by Allavena et al. already showed how the net amount of
Dextran-uptake by endocytosis, is increased following IL-10
treatment (11). Subgroup analysis based on CD14 and CD83
expression now allows a refined interpretation: in GM/IL4moC
cells endocytosis is highest and it is unaffected by exogenous
IL-10 (Figure 5C, left panel). In comparison, focusing solely on
R848-induced CD14+ cells, uptake was lower. Using the MFI
of unactivated GM/IL4moC after 1 h of Dextran-uptake as the
internal reference for the individual experiments, we analyzed
how Dextran-uptake varies in R848-activated moC and the
influence of IL10: Figure 5C, right panel, first shows pooled data
of 7 independent experiments, comparing Dextran uptake within
the total cell population. In this analysis, IL10 treatment resulted
in a highly significant increase in Dextran uptake, when using the
1 h time point as point of comparison. This could be interpreted
as a direct effect of IL-10 on the capacity to do endocytosis, as has
beenmentioned in previous reports (11, 30). However, Figure 5C
also shows that there is no difference between IL10-treated vs. un-
treated groups, once CD14+ and CD83+ subgroups are analyzed
separately. This means, that there is no dose-dependent effect
of exogenous IL-10 on the cells, once the cells have switched to
a macrophage-like cell type. This switch is the key event that
defines function and phenotype and this step is supported by
exogenous IL-10.
Given the heterogenous populations arising from monocytes,
we were interested, whether we could detect interactions
between these cell populations. Specifically, we asked how
IL10/R848moC
CD14+ affect autologous GM/IL4moC in the absence
of exogenous IL-10. For this experiment, two “effector”
populations were generated either by using LPS/IFNγ as a full
type 1- stimulus or IL-10 followed by R848 to induce a CD14+
population. Twenty four hour after treatment, these two cell
preparations were washed and stained with a membrane dye.
Subsequently, cells were added at a 1:1 ratio to autologous
GM/IL4moC
dye− for another 24h. Then R848 was added to the
groups to induce differentiation in GM/IL4moC
dye− followed
by FACS analysis 24 h later. Based on the staining with the
cell tracker, the “effector” population was separated from the
GM/IL4moC
dye− population. In the exemplary experiment shown
in Figure 5D, R848 alone induced 13% of CD14+ cells in the
presence of LPS/IFNmoC
dye+D14− (Figure 5D). In contrast, when
IL10/R848moC
dye+ were used as “effectors,” the fraction of CD14+
cells within the moCdye− population more than doubled. Similar
results were observed when evaluating CD163 expression in the
same context. Due to the complexity of this experimental setup,
using different preparations of primary cells analyzing sequential
events, the overall variation within the three experiments
performed is too high, to demonstrate statistical significance.
However, the experiment shown in Figure 5D is representative
of the effects observed. We conclude that even in conditions,
where no exogenous IL-10 is present, activated, CD14-polarized
cells are capable of affecting unpolarized bystander cells within a
culture period of 48 h.
Antigen-Specific T-Cells Are Affected
During Priming and Expansion
by IL10/R848moC
D14+
Next, we wanted to assess the role of IL10/R848moC
CD14+
in the context of antigen-specific T-cell activation. There is
ample evidence, how regulatory DC affect-cell activation in
the context of mixed leucocyte reactions or in response to a
CD3/CD28 stimulus (15). Thus, without repeating these assays,
it is a safe assumption that cells generated in our hands would
have a similar functional profile. We wanted to extend the
findings by looking at a more specific and physiological way
to activate T-cells. We focused on antigen-specific priming of
naïve CD8+ T-cells, using a well-validated experimental system
(19, 20). This experimental set-up is calibrated in a way that
naïve T-cells specific for the melanosomal peptide antigen
Melan-A(26−35(A27L)can be efficiently activated, starting from an
estimated precursor frequency of 1–10 in 10,000, meaning 20–
200 specific T-cells per well-within the starting population, and
expanding to a robust, specific cell population of at least 20% at
day 10 of culture.
We compared the stimulatory capacity of peptide-pulsed
R848moC vs. IL10/R848moC. As seen for an exemplary experiment
in Figure 6A, Expansion of MHC-multimer+ T-cells by day
10 was much lower (10.6%) when IL10/R848moC were used
(which consisted of 20% CD14+ cells). In comparison R848moC
(with a fraction of 4% CD14+ cells) gave yield to 26.4% of
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FIGURE 5 | IL-10-mediated effects on the function of moC. (A) IL-12 production is reduced. moC were preincubated with IL-10 (or not) and activated either with
R848 or a cytokine cocktail. 1 h later, brefeldin A was added for 4 h and cells subsequently stained for intracellular IL-12 and IL-8. Distinction between CD14 and
CD83 in the same samples is not possible, as CD14 upregulation is hindered by brefeldin A. CD14(y-axis)- and CD83(x-axis)-staining of a corresponding parallel
sample (without brefeldin A) is shown as an inserted dot plot. (n = 3) (B) IL-6 concentration in the supernatant of differentially treated and activated moC, —pooled
data from 5 experiments (*p < 0.05) (C). APC-dextran uptake over time in different cell populations. The left panel shows the MFI for Dextran after 1 h of GM/IL4moC
with or without IL-10 (7 experiments). The right panel shows the analysis of activated cells with or without IL-10. Analysis was either done on total cells, or gated on
CD14+ or CD83+ cells, respectively. 1–5 indicates the duration of dextran incubation (1 = 0min, 2 = 20min, 3 = 40min, 4 = 60min, 5 = 90min). Each value is
normalized to the MFI of GM/IL4moC at 1 h within the individual experiment (7 experiments). (D) Transmission of the CD14
+ phenotype onto non-committed
bystander moC. Two ‘effector’ populations were generated either by using LPS/IFNγ as a full type 1- stimulus or IL-10 followed by R848 to induce a CD14+
population. After 16 h they were stained with cell tracker dye and mixed at a 1:1 ratio with non-committed, autologous GM/IL4moC. Twenty four hours later R848
was added to this co-culture. Cells were then analyzed the next day and separated on the basis of the membrane dye. Examplary plot of 1 out of 3 experiments.
antigen-specific T-cells by day 10. Phenotypically, IL10/R848moC-
expanded T-cells expressed less CD62L in comparison to
the R848moC primed T-cells. Non-specific bystander T-cells
in both groups predominantly retained CD62L expression,
indicating that the reduced CD62L expression is due to the
specific cell-cell interaction and not due a globally altered
microenvironment. The antigen-specific T-cells also proliferated
less upon restimulation, which indicates antigen-specific
tolerance. The limitations of this assay certainly is the inter-donor
variation, as variation in the moC preparation (as documented
in Figure 1) combines with donor dependent variation due
to the low frequency of antigen-specific naïve CD8+ T-
cells. However, three separate experiments, (summarized in
Figure 6B), analyzing between 1 and 4 separate wells, depending
on the available cell material, show a comparable pattern
with reduced antigen-specific cell numbers, once IL10 was
involved as well as reduced CD62L expression. Therefore,
similar to the findings with non-specific clonal stimulation
or stimulation of memory T-cells shown in earlier work (15),
antigen-specific T-cell priming from the naïve T-cell repertoire
is quantitatively and qualitatively affected by IL-10 induced
moCCD14+ as well.
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FIGURE 6 | Effects of IL-10-treated moC on antigen-specific priming of naive T-cells. (A) moC were differentially treated (left panel) and pulsed with Melan-A peptide.
They were then used to prime naive CD8+ T-cells. After 10 days of culture using IL-21, IL-7, and IL-15, MHC-multimer+ cells were determined and phenotypically
characterized. T-cells were then restimulated with peptide-pulsed moC and MHC-multimer+ cells were re-evaluated 7 days later. Right panels depict the cell expansion
in absolute numbers. (B) Summary of three different experiments from different donors. Depending on the cell numbers available (number of APC and number of naïve
T-cells), experiments were set up in 1–4 parallel wells. The left panel shows the absolute numbers of antigen-specific (MHC-multimer+) cells per well after 10 days of
expansion (based on the precursor frequency the starting cell number in each well varies between 20 and 200 cells). The middle panel summarizes MFI-values for
CD62L of the resulting MHC-multimer+ cells. The right panel shows the ratio of the CD62L MFI of specific vs. non-specific CD8+ cells within the same sample.
DISCUSSION
We here provide a new view of how IL-10 affects monocytic
cells in culture: instead of assessing its effects on the bulk
culture, the identification of mutually exclusive expression of
CD14 or CD83 defines heterogeneity within the culture of
monocytic cells, which is greatly augmented by exogenous IL-
10 in combination with TLR-triggering. Thus, exogenous IL-
10 drives a population shift toward macrophages, but it does
not—for the most part—affect individual marker expression
(such as CD86) of function (such as endocytosis) within the
respective subgroup: IL10/actmoC
CD83+ (dendritic cells) do not
express less CD86 than their non-IL-10-treated counterparts;
IL10/actmoC
CD14+ (macrophages) do not take up more Dextran
than non-IL10-treated actmoC
CD14+.
The strong effects seen in the analyses of total cells, which is
repeatedly reported in various papers (2, 17, 21, 22), now finds
an explanation as a quantitative shift of different cell populations
and not a qualitative change of one homogenous dendritic
cell population. The shift toward macrophage-like cells alone,
and not differences in expression level on differently treated
cells, explains for example, why ILT4, an important myeloid-
specific receptor to suppress pro-inflammatory responses (31),
suddenly seems increased in the total cell population upon
IL10-treatment. Thus, at least three populations need to be
distinguished, and analyzed separately, based on CD14 and
CD83 expression: committed moCCD14, moCCD83 and non-
committed moCCD14−CD83−.
The phenotype- and function-altering effects of IL-10 on
immature DC have been known for a long time (15). Early
studies by Allavena et al. show, how IL-10 shifted monocytic cells
toward macrophages with maintained CD14 expression (11).
Of note, in that work, the IL-10 effect was lost, if IL-10 was
added at a later time point (e.g., day 3) and no upregulation
of CD14 was observed. In a recent paper, GM/IL4moC cultured
in the presence of IL-10, from the beginning of culture, were
termed “MDSC-like.” In this work, upregulation of CD14 has
been noted, and interpreted as an indicator for the retention
of the monocytic phenotype (12). The protocol to generate
prototypic tolerogenic dendritic cells is also based on IL-10,
added later at the time of cell activation (15, 24). In an effort
for harmonization of the clinical use of tolerogenic dendritic
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cells, CD11b+CD14++CD163++CD80+CD86+HLA-DR++
cells have been termed DC-10, arising from monocytes in a
process termed “arrested immaturity” (8).
The other critical finding in this work is that CD14, rather
than serving as a lineage marker (32), can be re-expressed
to indicate alternative cell differentiation toward macrophages.
Once moC receive a double stimulus consisting of IL-10 first
and TLR-agonist second, CD14 and CD83 serve as mutually
exclusive markers to define two cell populations with a different
phenotypical and functional profile. Thus, CD14 expression may
be less a question of halted differentiation (maintained CD14
expression) (27), rather than a sign of active re-expression
as part of the differentiation pathway toward a macrophage-
like cell.
Monocyte-derived DC are clinically evaluated as therapeutic
DC vaccination for cancer (33). For this purpose, CD83,
CD86, and HLA-DR often serves as read-out to assess optimal
stimuli (17, 34). Our findings are highly relevant in this
context, as the precise definition of a potentially suppressive
CD83− subgroup within the DC preparation may help to
better understand its effects (or lack thereof). Many studies
focus on finding the optimized stimulation cocktail, providing
the best Th1-oriented stimulation for these cells. Our pre-
incubation experiments with TNFα show that rather than the
right combination and dose of the stimulus, the timing, and
sequence of activation may be most relevant to counteract
intrinsic priming by endogenous IL-10 (Figure 2). Once CD14
is fully re-expressed, cells do not convert back to a CD83+
inflammatory phenotype.
Likewise in studies on “regulatory DC” the main
phenotypical description of such cells is that they express
less stimulatory markers (8, 24). Few inhibitory molecules
such as ILT4 and CD273 (PD-L2) (17) are known to
be expressed at a higher level, but these molecules are
not exclusive for a regulatory phenotype. In comparative
studies on protocols on the generation of regulatory DC
relevant for clinical use, no attention is paid to CD14
expression (24, 35, 36). However, as we now show, CD14,
combined with a panel of macrophage markers (Figure 4),
positively identifies cells with a stable phenotype and
regulatory function.
Functionally, we aimed to add to the known characteristics of
IL-10-treated cells. Distinction based on CD14 expression reveals
that exogenous IL-10 itself does not directly enhance endocytosis
as suggested earlier (11, 37), but changes the cellular composition.
Moreover, moCCD14+ have the capacity to affect non-committed
bystander cells, steering them toward the CD14+ phenotype
once an additional TLR trigger is provided. Although seen in
an artificial experimental system with a broad range of variation,
this effect may have implications in tumor biology. Once tumor-
associated factors dominate the micromilieu and reverse some
of the surrounding myelomonocytic cells to tumor-associated
macrophages (TAMs), these TAMs may be able to recruit non-
committed bystander cells, especially if an additional TLR-trigger
is provided, thereby multiplying the tumor-associated effects.
Mere activation of the immune infiltrate, e.g., by a TLR-trigger,
may cause unintended, suppressive effects, if cells are primed by
IL-10, requiring a more orchestrated intervention (38, 39).
Suppression of T-cell responses is a known hallmark of
regulatory DCs. We chose to evaluate functional differences
in the context of antigen-specific priming of human, naïve
CD8+ T-cells (19, 20). Peptide-pulsed IL10/R848moC are poor
stimulators of a de novo T-cell response and the T-cells are
tolerant to a second stimulus. Interestingly, despite reduced
proliferation, CD62L expression is lower than in fully activated T-
cells. This corroborates, on the level of a de novo antigen-specific,
human immune response, data on the effects of myeloid-derived
suppressor cells from murine models (40, 41).
The caveat of these experiments is, that, to some extent,
monocyte-derived DCs, are in itself a culture artifact (42).
For murine bone marrow cultures, Helft et al. showed,
that these cultures are not monomorphic but comprise of
conventional DCs and monocyte-derived macrophages (43).
Our data extend these findings to human mononuclear cells
showing that culture with GM-CSF and IL-4 is not sufficient to
definitively tilt monocytes toward DC differentiation. However,
understanding how such cell populations, serving as cell
therapeutics, may develop and how they might deviate from
the projected path is essential to understand their potential
clinical impact. For cancer patients significant difficulties have
been described to generate fully activated DCs for clinical
use and this deficiency has been linked to the presence of
regulatory CD14+HLA-DRlo/neg cells (44). For example, an
insufficiently activating vaccine may not be a “null” event,
but might even have a negative effect (45). Filipazzi et al.
described the occurrence of CD14+HLA-DR−/low cells with
immunosuppressive characteristics following vaccination with
GM-CSF and hsp gp96 in melanoma patients (46). Llopiz et al.
also observed that IL10-producing “immunosuppressive DC”
are induced by therapeutic vaccination with imiquimod-based
vaccines, significantly affecting T-cell responses in a murine
model (47). Other groups observed elevated levels of IL-10
following vaccination with imiquimod, suggesting that besides
the inflammatory activity, a self-regulatory, IL-10-dependent
pathway is being triggered. The authors discuss the possibility of
using IL-10 blockade clinically, to enhance vaccine effects (48).
In this context and in light of our data, it will be interesting to
test in vivo, whether priming of the vaccination site with TNFα
prior to local administration of the TLR-trigger may overcome
the described IL-10-dependent pathway.
In summary mutually exclusive, CD14 and CD83-expression
in GM/IL4moC provides a means to understand functional
differences of therapeutically used cell products better. For IL-
10, these differences are, for the most part, based on shifts in
the magnitude of the respective cell populations rather than
a direct regulation on a single molecule level. These findings
will help to better design and define cellular products and
might help to understand the variable outcome of vaccination in
different individuals. Given the prominent role of IL-10 in tumor
immunology and the emerging role of CD14+HLA-DRlowMDSC
in human diseases, these findings may also have a biologically
significant counterpart.
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